Table of Contents
ISRN Hematology
Volume 2013 (2013), Article ID 908191, 9 pages
Research Article

Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study

1Division of Haematology, Department of Internal Medicine, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cd., No. 181, Kocamustafapasa-Fatih, 34098 Istanbul, Turkey
2Division of Haematopathology, Department of Pathology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
3Department of Biostatistics, Hacettepe University Medical Faculty, Ankara, Turkey
4Department of Infectious Diseases, Koç University Medical School, Istanbul, Turkey

Received 5 June 2013; Accepted 9 July 2013

Academic Editors: L. Bordin, A. Bosly, D. Del Principe, K. Oritani, and F. W. Quelle

Copyright © 2013 Murat Ozbalak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this single-center, retrospective study was to investigate the impact of rituximab, reconsider the validity of International Prognostic Index (IPI), and evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort. Three hundred twelve diffuse large B cell lymphoma patients (median age: 52) were included. Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; ) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.; ). In the young, low risk patient subgroup (aaIPI = 0&1; ), rituximab improved 3- and 5-year PFS and OS rates ( and , resp.). The efficacy of rituximab in young high risk patients was comparable to the literature. CoO data were available in 190 patients. The OS at 3 years was 79% for GC and 64% for non-GC subgroups ( ). To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. CoO was not an independent risk factor for prognosis in the multivariate analysis although patients with GC showed a significant survival advantage in the univariate analysis. CoO was also found to be a significant determinant of response in refractory/relapsed patients. Our results confirm the efficacy of rituximab in low and high risk, young patients outside of a randomized clinical trial setting.